Caner B, Kitapçl M, Unlü M, Erbengi G, Calikoğlu T, Göğüş T, Bekdik C
Department of Nuclear Medicine, Hacettepe University Medical Faculty, Ankara Oncology Hospital, Turkey.
J Nucl Med. 1992 Mar;33(3):319-24.
The potential of hexakis (methoxyisobutylisonitrile) technetium (1) (MIBI) for the imaging of various bone pathologies and for assessment of effectiveness of therapy were investigated in a prospective study. MIBI was evaluated in comparison to MDP bone scans in 73 bone lesions (31 benign, 42 malignant). With MIBI, all but six malignant lesions were clearly visualized and the mean lesion/contralateral (L/C) ratio (2.21 +/- 1.17) was significantly higher than that of benign counterparts (1.26 +/- 0.40) (p less than 0.0005). No such significance was detected on corresponding MDP bone scans (4.86 +/- 3.48 versus 3.11 +/- 1.52). Ten cases with malignant tumor underwent both pre- and post-therapy MIBI evaluation and it was demonstrated that radiotherapy and/or chemotherapy significantly inhibited MIBI uptake. Moreover, post-therapeutic MIBI uptake was a good reflection of the effectiveness of therapy as confirmed by histopathological evaluation. Thus, with a strikingly higher uptake in malignant bone lesions MIBI might have good potential for the detection of malignant bone pathologies as well as for assessing tumor response to therapy.
在一项前瞻性研究中，研究了六甲基异丁基异腈锝（1）（MIBI）对各种骨病变进行成像以及评估治疗效果的潜力。在73处骨病变（31处良性，42处恶性）中，将MIBI与MDP骨扫描进行了比较评估。使用MIBI时，除6处恶性病变外，所有病变均清晰可见，平均病变/对侧（L/C）比值（2.21±1.17）显著高于良性病变（1.26±0.40）（p<0.0005）。在相应的MDP骨扫描中未检测到这种显著性差异（4.86±3.48对3.11±1.52）。10例恶性肿瘤患者在治疗前和治疗后均接受了MIBI评估，结果表明放疗和/或化疗显著抑制了MIBI摄取。此外，治疗后MIBI摄取情况很好地反映了治疗效果，这一点已得到组织病理学评估的证实。因此，由于MIBI在恶性骨病变中的摄取显著更高，它在检测恶性骨病变以及评估肿瘤对治疗的反应方面可能具有良好的潜力。
